Introduction: In the halls of Congress there is widespread
agreement about the role of R&D in the success of the America’s most innovative
corporations. However, too often lawmakers view government models of discovery,
from NASA to public university research labs, as obsolete and costly superstructures
in today’s .com marketplace. What
happened to the case for public exploration and discovery and why shouldn’t the
private sector be trusted to find the cure for Grandma’s dementia or Johnny’s
brain tumor? Long-time Washington
political insider, former lobbyist, Administration appointee, and AIMBE’s Executive
Director, Milan Yager, will reveal the hidden truth about why Congress doesn’t
fund needed biomedical research.
and Discussion: This
presentation will highlight innovations and achievements made possible from
past federal investments in basic research; such as the internet, wireless
communications, even mapping the human genome.
Today, Congress seems less interested in past accomplishments as they
assume new priorities to balance the budget, reduce government, and free the
private sector to assume long-standing government responsibilities for
innovation and discovery. How did
Congress make spending decisions to permit federal R&D spending to be flat
for over a decade? Learn about why Congress is no long accountable for reduce
investments in basic research. Discover
three secrets to making a winning case for federal funding for medical and
biological research. Learn practical
steps to successfully getting your point across to a Member of Congress. Find out how to brand your research as the
Sputnik in the race to cure cancer, manage chronic disease, or Type I diabetes.
Conclusions: Arming yourself with the strategies for the
political warfare in the case for innovation is more than just changing public
policy; it can provide the key to changing the future landscape of new
biomedical materials, products or procedures.
Attendees will get insight into America’s next biomedical “moonshot”